PMID- 35414201
OWN - NLM
STAT- MEDLINE
DCOM- 20220511
LR  - 20220511
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 18
IP  - 18
DP  - 2022 Jun
TI  - Long-term safety and efficacy of bisphosphonate therapy in advanced lung cancer 
      with bone metastasis.
PG  - 2257-2267
LID - 10.2217/fon-2022-0098 [doi]
AB  - Aim: This retrospective, observational study evaluated the long-term (>12 months) 
      safety and effectiveness of bisphosphonate. Methods: Data collected for 359 
      patients included quantity and proportion of adverse events (AEs) and 
      skeletal-related events (SREs), and times to first AE and first SRE. Results: 
      Patients in the </=24-month group experienced significantly fewer AEs compared with 
      the >24-month treatment group (p = 0.008), and treatment for >24 months was a 
      potential risk factor for AEs (p = 0.05). Neither the proportion nor the risk of 
      SRE was significantly associated with therapy duration (p = 0.525 and 0.084, 
      respectively). Conclusion: Bisphosphonate treatment beyond 2 years may increase 
      the risk of AEs, but may prolong SRE-free survival early after 24 months, 
      compared with medication administered for </=24 months.
FAU - Wei, Zixin
AU  - Wei Z
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
FAU - Pan, Bo
AU  - Pan B
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
FAU - Jia, Dexin
AU  - Jia D
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
FAU - Yu, Yan
AU  - Yu Y
AUID- ORCID: 0000-0001-5598-763X
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220413
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Diphosphonates)
SB  - IM
MH  - *Bone Neoplasms/drug therapy/secondary
MH  - Diphosphonates/adverse effects
MH  - Humans
MH  - *Lung Neoplasms/pathology
MH  - Retrospective Studies
MH  - Risk Factors
OAB - The survival of patients with lung cancer with bone metastases has improved, just 
      as the outcomes for many patients with cancer have improved. Bisphosphonate is 
      the standard drug used for bone metastasis of lung cancer, but its safety and 
      effectiveness when used for more than 2 years have not been finally decided. This 
      study reviewed and analyzed the records of 359 patients who received 
      bisphosphonate treatment for up to 24 months or longer than 24 months. It was 
      determined that bisphosphonate used for more than 24 months may increase the risk 
      of calcium deficiency in the bloodstream (hypocalcemia) and kidney disease, but 
      may also delay the development of bone pain, fracture and spinal cord compression 
      or the need for bone radiotherapy or surgery.
OABL- eng
OTO - NOTNLM
OT  - adverse events
OT  - bisphosphonate
OT  - bone metastasis
OT  - long-term
OT  - lung cancer
OT  - skeletal-related events
EDAT- 2022/04/14 06:00
MHDA- 2022/05/12 06:00
CRDT- 2022/04/13 05:26
PHST- 2022/04/14 06:00 [pubmed]
PHST- 2022/05/12 06:00 [medline]
PHST- 2022/04/13 05:26 [entrez]
AID - 10.2217/fon-2022-0098 [doi]
PST - ppublish
SO  - Future Oncol. 2022 Jun;18(18):2257-2267. doi: 10.2217/fon-2022-0098. Epub 2022 
      Apr 13.